Oncothyreon Inc (USA)  

(Public, NASDAQ:ONTY)   Watch this stock  
Find more results for Nasdaq:ONTY
3.49
+0.48 (15.95%)
After Hours: 3.45 -0.04 (-1.15%)
May 26, 7:59PM EDT  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 2.95 - 3.56
52 week 1.41 - 3.60
Open 3.02
Vol / Avg. 21.93M/3.91M
Mkt cap 327.65M
P/E     -
Div/yield     -
EPS -0.55
Shares 102.30M
Beta 1.05
Inst. own 63%
Aug 10, 2015
Q2 2015 Oncothyreon Inc Earnings Release (Estimated) Add to calendar
May 11, 2015
Q1 2015 Oncothyreon Inc Earnings Call - Webcast
May 11, 2015
Q1 2015 Oncothyreon Inc Earnings Release
Mar 10, 2015
Q4 2014 Oncothyreon Inc Earnings Call - Webcast
Mar 10, 2015
Q4 2014 Oncothyreon Inc Earnings Release
Mar 4, 2015
Oncothyreon Inc at Cowen Health Care Conference
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '15) 2014
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -28.84% -55.16%
Return on average equity -32.22% -61.37%
Employees 49 -
CDP Score - -

Address

2601 4th Ave Ste 500
SEATTLE, WA 98121-3222
United States - Map
+1-206-8012100 (Phone)
+1-206-8012101 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Oncothyreon Inc. (Oncothyreon) is a clinical-stage biopharmaceutical company focused primarily on the development of therapeutic products for the treatment of cancer. The Company’s cancer vaccines are designed to stimulate the immune system to attack cancer cells, while its small molecule compounds are designed to inhibit the activity of specific cancer-related proteins. Its lead product candidate, tecemotide (formerly known as L-BLP25 or Stimuvax), is being evaluated for the treatment of non-small cell lung cancer (NSCLC). It has granted worldwide license to Merck KGaA of Darmstadt, Germany (Merck KGaA), for the development, manufacture and commercialization of tecemotide. It is conducting a Phase I trial for ONT-10, a cancer vaccine directed against the same target as tecemotide. It is also collaborating with Array BioPharma Inc. (Array) to develop and commercialize ONT-380, an orally active, reversible and selective small-molecule HER2 inhibitor.

Officers and directors

Robert L. Kirkman M.D. President, Chief Executive Officer, Director
Age: 66
Bio & Compensation  - Reuters
Julia Marie Eastland Chief Financial Officer, Vice President - Corporate Development, Secretary
Age: 49
Bio & Compensation  - Reuters
Gary W Christianson Chief Operating Officer
Age: 60
Bio & Compensation  - Reuters
Jay Venkatesan M.D. Executive Vice President, General Manager
Age: 45
Bio & Compensation  - Reuters
Scott Peterson Ph.D. Chief Scientific Officer
Age: 53
Bio & Compensation  - Reuters
Diana Hausman M.D. Chief Medical Officer
Age: 51
Bio & Compensation  - Reuters
Christopher S. Henney Ph.D. Non-Executive Independent Chairman of the Board
Age: 74
Bio & Compensation  - Reuters
Richard L. Jackson Ph.D. Independent Director
Age: 75
Bio & Compensation  - Reuters
Steven P. James Independent Director
Age: 56
Bio & Compensation  - Reuters
Ted W. Love M.D. Independent Director
Age: 56
Bio & Compensation  - Reuters